Relief of Discomfort

X49 Research

Studies Summary:

What is the X49 Patch?

X49 patch is a companion non-transdermal, light-reflecting patch to the X39. While X39 focuses on general tissue repair via the GHK-Cu peptide, the X49 patch is designed to stimulate a different copper peptide (AHK-Cu), which targets muscle development, bone density, strength endurance, and cardiovascular stamina.


Key Findings & What They Mean

  • Restoring Youthful Peptide Levels: Blood tests over a 60-day trial showed that wearing the patch significantly increased AHK-Cu peptide utilization rates, helping push cellular metrics back to levels typically seen in younger adults.

  • Massive Gains in Physical Strength: In a 60-day exercise trial for adults aged 40–81, participants wearing the X49 patch saw dramatic performance improvements ranging from 31% to 70% across exercises like sit-ups, squats, bicep curls, and grip strength—significantly outperforming what is typically expected from exercise alone at that age.

  • Better Cardiovascular Stamina: 3-minute exercise bike tests confirmed statistically significant increases in top speed and total distance covered by Day 60, showing notable gains in overall aerobic endurance and leg muscle stamina.

  • Protecting Bone Density: In a trial tracking bone breakdown markers (like serum NTx and Hydroxyproline), the patch helped produce a significant drop in osteoclastic bone resorption—indicating a reduction in bone breakdown during the body's natural repair cycles.

  • Mood, Sleep, and Brain Chemistry Support: Metabolic testing showed that X49 actively supported both the dopamine and serotonin pathways, leading to participants reporting reduced stress, less feelings of depression, and better overall sleep quality.

  • Fueling the Body with Amino Acids: Urine metabolite testing revealed wide-reaching positive shifts across 14 amino acids, confirming that the body was actively consuming and utilizing essential building blocks (like lysine and leucine) for tissue and muscle remodeling.

  • Better Posture and Lower Stress: Alongside a statistically significant drop in self-reported stress levels by Day 60, 3D body scans revealed visible postural improvements, such as reduced shoulder slumping and better torso alignment.

Clinical Studies:

Study Title: LifeWave X49 Patch Supports Improved Results in Fitness, Strength and Stamina

  • Study Type / Design: Open-label, longitudinal clinical trial with functional exercise performance testing.

  • Sample Size & Demographics: 20 completed male participants aged 40–81 (mean age ~63).

  • Intervention / Testing Period: Daily application of X49 phototherapy patches (worn 8–12 hours/day for 60 days) combined with a standardized exercise program (20 minutes of exercise 3 times per week using supplied exercise bikes, dumbbells, resistance bands, and hand grips). Testing occurred at Baseline (Day 1), Day 2, Day 7, Day 14, Day 30, and Day 60.

  • Key Metrics Measured: Physical fitness & strength metrics (3-minute exercise bike distance and speed, push-ups, sit-ups, squats, bicep curls, grip strength, resistance band reps/weight); Styku 3D body scans; blood AHK-Cu peak and utilization levels; salivary/urine amino acid panels; standard questionnaires (PASE, GPAQ, SEQ, AIOS-VAS, Stress Scale, REAP-S).

  • Primary Results & Findings: Demonstrated statistically significant improvements in exercise performance, strength, and stamina ranging from 31% to 70% across all physical fitness outcomes over 60 days (\(p < 0.05\)). Exercise bike stamina showed highly significant gains in speed (Day 30 \(p = 0.03\), Day 60 \(p = 0.01\)) and distance (Day 30 \(p = 0.005\), Day 60 \(p = 0.0001\)). AHK peptide utilization showed a statistically significant increase from peak to maximum usage across all days (\(p < 0.0001\), Cohen's \(d = 1.35\)), returning peptide utilization rates to levels typical of individuals in their 20s and 30s. Subjective stress levels also showed a statistically significant reduction by Day 60 (\(p = 0.034\)).

LifeWave X49 Patch Supports Improved Results in Fitness, Strength and Stamina.pdf

Study Title: Bone and Muscle Support in Ageing Women with LifeWave X49 Patch

  • Study Type / Design: Open-label, longitudinal clinical trial (evaluating X49 alone vs. X49 in combination with X39).

  • Sample Size & Demographics: 24 women enrolled, 17–18 completing all assessment time points (women aged 40–80).

  • Intervention / Testing Period: X49 patch applied daily (at acupuncture point GB34) alone or in combination with X39 patch (at CV6 or GV14) over 60 days. Dietary intake monitored via food logs requiring a minimum of 6 oz of leucine-rich foods daily. Assessments occurred at Baseline (Day 1), Day 2, Day 7, Day 14, Day 30, and Day 60.

  • Key Metrics Measured: Serum N-telopeptide (NTx, a primary biomarker of osteoclastic bone resorption); serum Hydroxyproline (diagnostic marker of bone turnover); blood plasma AHK-Cu levels; urinary amino acid panels (14 pathway amino acids, 2-aminoadipic acid); catecholamine/serotonin pathway neurotransmitters (dopamine, 5-HT).

  • Primary Results & Findings: Showed a significant >30% reduction in NTx-creatine levels across post-baseline assessment time points (28%–44% response rate), indicating a statistically meaningful reduction in osteoclastic bone breakdown. Hydroxyproline levels decreased significantly across 5 data points (\(p < 0.05\)). Blood AHK-Cu levels showed a statistically significant decrease by Day 30 (\(-12.65\text{ ng/ml}\), \(p = 0.0489\)), reflecting active uptake and utilization of AHK-Cu for tissue and bone matrix remodeling. 14 amino acids demonstrated statistically significant shifts across dopamine, serotonin, glutaminergic, and transsulfuration pathways over 60 days, with statistically significant support for the dopamine pathway (Day 2 and Day 30) and serotonin (5-HT) pathway, contributing to improved mood and sleep in menopausal/post-menopausal participants.

Bone and Muscle Support in Ageing Women with LifeWave X49 Patch.pdf

Study Title: LifeWave X49 Patch Proof of Concept Explores Changes in the AHK-Cu Peptide in Blood

  • Study Type / Design: Open-label, single-arm proof-of-concept pilot study (pre-post convenience sample).

  • Sample Size & Demographics: 10 adult participants (men and women aged 40–81).

  • Intervention / Testing Period: X49 non-transdermal patch applied daily for 7 days (placed at GV14 or CV6). Blood draws performed at Baseline (Day 1), 24 Hours (Day 2), and Day 7.

  • Key Metrics Measured: Blood plasma concentration of L-alanine-L-histidyl-L-lysine copper (AHK-Cu) tripeptide quantified via mass spectrometry (AxisPharm).

  • Primary Results & Findings: 50% of participants exhibited increases in AHK-Cu levels over baseline during the 7-day period. However, across the total sample (\(N=10\)), the overall change did not reach statistical significance (\(p > 0.05\)). Sub-analysis revealed that dietary lysine/leucine deficiencies in vegetarian subjects impacted peptide synthesis; when vegetarian participants were excluded, a clear pattern of increased mean AHK-Cu blood concentration emerged across the 7 days.

LifeWave X49 Patch Proof of Concept Explores Changes in the AHK-Cu Peptide in Blood.pdf